encoding them. These are then assembled in yeast libraries from which cells expressing potential binders are sorted and the proteins identified using deep sequencing. This pipeline ultimately results in the identification of thousands of high-affinity binders. Further analysis of which predicted binders do bind and which don't is used to refine the computational model, thus completing the design cycle.
These landmark efforts build off the group's long-term goal of figuring out how sequence impacts folding and stability and their use of iterative cycles to improve computationalbased design (e.g., Rocklin et al., 2017) .
To cap off their latest study, the authors choose individual peptides for additional proof-of-principle testing, including confirmatory crystal structures and evidence of in vitro and in vivo activity. Specifically, the influenza inhibitor is shown to have impressive efficacy in mouse models of infection, and the toxin inhibitor protects cultured rat cortical neurons.
It is also very important to note that repeated administration of the influenza-targeting small proteins does not elicit a strong immune response. This portends well for de novo designed small proteins as potential therapeutics, although further work is needed to fully explore their immunogenicity and determine whether additional steps in the design stages will be needed to filter out peptides with high immunogenic potential. It is also an open question whether computational analysis can be used to filter out small proteins that have greater potential for off-target effects.
Time to take out the crystal ball. What could this mean for a future bench researcher, who for example, might want to make a new inhibitor for a target protein? The starting point for such a project might one day be as simple as pulling up the structure, running a computer program, and ordering a few thousand oligonucleotides-perhaps an afternoon's work. What could a shift to massively parallel peptide design mean for the larger scientific community? The number of clinical trials based on small peptide therapeutics has been increasing in recent years. This should only accelerate given the speed and ease of protein synthesis methods coupled with these new computational tools. Perhaps in a decade, the majority of new filings for clinical trials will be for small designer proteins and not small molecules or antibodies.
